Copyright Reports & Markets. All rights reserved.

Global Spinal Muscular Atrophy Medicine Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Spinal Muscular Atrophy Medicine Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Product
      • 1.4.2 LMI-070
      • 1.4.3 ND-602
      • 1.4.4 NT-1654
      • 1.4.5 Nusinersen
      • 1.4.6 NXD-30001
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Spinal Muscular Atrophy Medicine Market Size
      • 2.1.1 Global Spinal Muscular Atrophy Medicine Revenue 2014-2025
      • 2.1.2 Global Spinal Muscular Atrophy Medicine Sales 2014-2025
    • 2.2 Spinal Muscular Atrophy Medicine Growth Rate by Regions
      • 2.2.1 Global Spinal Muscular Atrophy Medicine Sales by Regions
      • 2.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
      • 3.1.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
      • 3.1.2 Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers
      • 3.1.3 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI)
    • 3.2 Spinal Muscular Atrophy Medicine Revenue by Manufacturers
      • 3.2.1 Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2014-2019)
    • 3.3 Spinal Muscular Atrophy Medicine Price by Manufacturers
    • 3.4 Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Product Types
      • 3.4.1 Spinal Muscular Atrophy Medicine Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Spinal Muscular Atrophy Medicine Product Type
      • 3.4.3 Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Spinal Muscular Atrophy Medicine Sales by Product
    • 4.2 Global Spinal Muscular Atrophy Medicine Revenue by Product
    • 4.3 Spinal Muscular Atrophy Medicine Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Spinal Muscular Atrophy Medicine Breakdown Data by End User

    6 North America

    • 6.1 North America Spinal Muscular Atrophy Medicine by Countries
      • 6.1.1 North America Spinal Muscular Atrophy Medicine Sales by Countries
      • 6.1.2 North America Spinal Muscular Atrophy Medicine Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Spinal Muscular Atrophy Medicine by Product
    • 6.3 North America Spinal Muscular Atrophy Medicine by End User

    7 Europe

    • 7.1 Europe Spinal Muscular Atrophy Medicine by Countries
      • 7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Countries
      • 7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Spinal Muscular Atrophy Medicine by Product
    • 7.3 Europe Spinal Muscular Atrophy Medicine by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Spinal Muscular Atrophy Medicine by Countries
      • 8.1.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Countries
      • 8.1.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Spinal Muscular Atrophy Medicine by Product
    • 8.3 Asia Pacific Spinal Muscular Atrophy Medicine by End User

    9 Central & South America

    • 9.1 Central & South America Spinal Muscular Atrophy Medicine by Countries
      • 9.1.1 Central & South America Spinal Muscular Atrophy Medicine Sales by Countries
      • 9.1.2 Central & South America Spinal Muscular Atrophy Medicine Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Spinal Muscular Atrophy Medicine by Product
    • 9.3 Central & South America Spinal Muscular Atrophy Medicine by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Spinal Muscular Atrophy Medicine by Countries
      • 10.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Countries
      • 10.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Spinal Muscular Atrophy Medicine by Product
    • 10.3 Middle East and Africa Spinal Muscular Atrophy Medicine by End User

    11 Company Profiles

    • 11.1 Astellas Pharma Inc.
      • 11.1.1 Astellas Pharma Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
      • 11.1.5 Astellas Pharma Inc. Recent Development
    • 11.2 AveXis, Inc.
      • 11.2.1 AveXis, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Products Offered
      • 11.2.5 AveXis, Inc. Recent Development
    • 11.3 Bioblast Pharma Ltd.
      • 11.3.1 Bioblast Pharma Ltd. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered
      • 11.3.5 Bioblast Pharma Ltd. Recent Development
    • 11.4 Cytokinetics, Inc. 24
      • 11.4.1 Cytokinetics, Inc. 24 Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered
      • 11.4.5 Cytokinetics, Inc. 24 Recent Development
    • 11.5 F. Hoffmann-La Roche Ltd.
      • 11.5.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered
      • 11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.6 Genethon
      • 11.6.1 Genethon Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered
      • 11.6.5 Genethon Recent Development
    • 11.7 Genzyme Corporation
      • 11.7.1 Genzyme Corporation Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered
      • 11.7.5 Genzyme Corporation Recent Development
    • 11.8 GMP-Orphan SAS
      • 11.8.1 GMP-Orphan SAS Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered
      • 11.8.5 GMP-Orphan SAS Recent Development
    • 11.9 Ionis Pharmaceuticals, Inc.
      • 11.9.1 Ionis Pharmaceuticals, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered
      • 11.9.5 Ionis Pharmaceuticals, Inc. Recent Development
    • 11.10 Longevity Biotech, Inc
      • 11.10.1 Longevity Biotech, Inc Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Products Offered
      • 11.10.5 Longevity Biotech, Inc Recent Development
    • 11.11 Neurodyn Inc.
    • 11.12 Neurotune AG
    • 11.13 Novartis AG
    • 11.14 Sarepta Therapeutics, Inc.
    • 11.15 Voyager Therapeutics, Inc.
    • 11.16 Vybion, Inc.
    • 11.17 WAVE Life Sciences Ltd.

    12 Future Forecast

    • 12.1 Spinal Muscular Atrophy Medicine Market Forecast by Regions
      • 12.1.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Regions 2019-2025
    • 12.2 Spinal Muscular Atrophy Medicine Market Forecast by Product
      • 12.2.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Product 2019-2025
      • 12.2.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Product 2019-2025
    • 12.3 Spinal Muscular Atrophy Medicine Market Forecast by End User
    • 12.4 North America Spinal Muscular Atrophy Medicine Forecast
    • 12.5 Europe Spinal Muscular Atrophy Medicine Forecast
    • 12.6 Asia Pacific Spinal Muscular Atrophy Medicine Forecast
    • 12.7 Central & South America Spinal Muscular Atrophy Medicine Forecast
    • 12.8 Middle East and Africa Spinal Muscular Atrophy Medicine Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Spinal Muscular Atrophy Medicine Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Spinal Muscular Atrophy Medicine market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Spinal Muscular Atrophy Medicine market based on company, product type, end user and key regions.

      This report studies the global market size of Spinal Muscular Atrophy Medicine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Spinal Muscular Atrophy Medicine in these regions.
      This research report categorizes the global Spinal Muscular Atrophy Medicine market by top players/brands, region, type and end user. This report also studies the global Spinal Muscular Atrophy Medicine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Astellas Pharma Inc.
      AveXis, Inc.
      Bioblast Pharma Ltd.
      Cytokinetics, Inc. 24
      F. Hoffmann-La Roche Ltd.
      Genethon
      Genzyme Corporation
      GMP-Orphan SAS
      Ionis Pharmaceuticals, Inc.
      Longevity Biotech, Inc
      Neurodyn Inc.
      Neurotune AG
      Novartis AG
      Sarepta Therapeutics, Inc.
      Voyager Therapeutics, Inc.
      Vybion, Inc.
      WAVE Life Sciences Ltd.

      Market size by Product
      LMI-070
      ND-602
      NT-1654
      Nusinersen
      NXD-30001
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Spinal Muscular Atrophy Medicine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Spinal Muscular Atrophy Medicine market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Spinal Muscular Atrophy Medicine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Spinal Muscular Atrophy Medicine submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Spinal Muscular Atrophy Medicine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Spinal Muscular Atrophy Medicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now